Citation Impact
Citing Papers
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
2016
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
2014
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Head and neck squamous cell carcinoma
2020 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Genetics and Genomic Studies in Scleroderma (Systemic Sclerosis)
2008
Biomarkers of response to PD-1/PD-L1 inhibition
2017
Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
2015
Image analysis and machine learning in digital pathology: Challenges and opportunities
2016 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
2016
Regulation of Interleukin-1β Transcription by Epstein–Barr Virus Involves a Number of Latent Proteins via Their Interaction with RBP
1998 StandoutNobel
Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte–associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer
2015
The immune contexture in cancer prognosis and treatment
2017 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Scleroderma
2009 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Chronic graft-versus-host disease
2003 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Proliferation and immunoglobulin secretion of lymphoblastoid cell lines are differently affected by soluble cytokines
1994
NKG2D engagement of colorectal cancer‐specific T cells strengthens TCR‐mediated antigen stimulation and elicits TCR independent anti‐tumor activity
2003
Endocrine side effects of cancer immunotherapy
2017
Hematopoietic Stem-Cell Transplantation
2006 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The −319C/+49G/CT60G Haplotype of CTLA-4 Gene Confers Susceptibility to Rheumatoid Arthritis in Mexican Population
2013
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
2015
Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies
2018
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
2015
Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA Haplotype
1998
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
2015
NK cells and cancer: you can teach innate cells new tricks
2015
Defining the Intensity of Conditioning Regimens: Working Definitions
2009 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time
2012
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
2015
Monitoring immune responses in the tumor microenvironment
2016
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
2018
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
2015
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells
2006
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling
2019
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Endocrinological side-effects of immune checkpoint inhibitors
2016
Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction
2000
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Improved disease-free–survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia
2002
Control of foreign Ag‐specific Ab responses by Treg and Tfr
2020 StandoutNobel
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
2017
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
2002 StandoutScience
Engagement of NKG2D by Cognate Ligand or Antibody Alone Is Insufficient to Mediate Costimulation of Human and Mouse CD8+ T Cells
2005 StandoutNobel
Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer
2014
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Works of Anna Morabito being referenced
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
2013
HLA‐C high resolution typing: analysis of exons 2 and 3 by sequence based typing and detection of polymorphisms in exons 1–5 by sequence specific primers
1998
CTLA‐4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis
2007
Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
2013
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
2012
CTLA-4 is expressed by human monocyte—derived dendritic cells and regulates their functions
2010
HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines
2004
Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience
1997
Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines.
1999
MicroRNA in Glioblastoma: An Overview
2017
European collection for biomedical research
1988
Association of −318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis
2007